The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
IMMU-130, a unique antibody-drug conjugate (ADC) of SN-38 targeting CEACAM5 antigen: Preclinical basis for clinical activity in metastatic colorectal cancer (mCRC).
 
Serengulam V. Govindan
Employment - Immunomedics
Stock and Other Ownership Interests - Immunomedics
Patents, Royalties, Other Intellectual Property - Immunomedics
 
Thomas M. Cardillo
Employment - Immunomedics
Stock and Other Ownership Interests - Immunomedics
 
Edmund A. Rossi
Employment - Immunomedics; Immunomedics (I)
Stock and Other Ownership Interests - Immunomedics; Immunomedics (I)
Patents, Royalties, Other Intellectual Property - Immunomedics
 
William J. McBride
Employment - Immunomedics
Stock and Other Ownership Interests - Immunomedics
Patents, Royalties, Other Intellectual Property - Immunomedics
 
Robert M. Sharkey
Employment - Immunomedics
Stock and Other Ownership Interests - Immunomedics
 
David M. Goldenberg
Employment - Immunomedics; Immunomedics (I)
Leadership - Immunomedics; Immunomedics (I)
Stock and Other Ownership Interests - Immunomedics; Immunomedics (I)
Patents, Royalties, Other Intellectual Property - Immunomedics